BTIG analyst Mark Massaro lowered the firm’s price target on Caris Life Sciences (CAI) to $32 from $38 and keeps a Buy rating on the shares. The company’s Q1 results delivered a modest beat, but the quarter was light on therapy selection volumes, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences price target lowered to $28 from $35 at Citi
- Analyst Reiterates Buy as Strong Revenue, Improving Profitability Offset Near-Term Risks; Price Target Trimmed to $31
- Caris Life Sciences Earnings Call Signals Profitable Surge
- Caris Life Sciences reports Q1 EPS 0c, consensus (2c)
- Caris Life Sciences still sees 2026 revenue $1.0B-$1.02B, consensus $1.01B